COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cogent Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$30.01+0.49 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Cogent Biosciences, Inc. revenue by segment
By business segment
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | YoY |
|---|---|---|---|---|---|---|---|---|
| Late-stage Development [Member] | $67.36M | $65.83M | $120.06M | $63.28M | $65.79M | $121.67M | $120.86M | +2.4% |
| R&D Personnel Related [Member] | $34.89M | $37.92M | $64.04M | $29.31M | $25.83M | $51.24M | $47.05M | +35.1% |
| Stock-Based Compensation Expense [Member] | $26.16M | $33.55M | $46.08M | $20.87M | $20.63M | $40.36M | $39.74M | +26.8% |
| Early-stage, Preclinical and Discovery Programs [Member] | $22.48M | $24.23M | $40.11M | $18.73M | $15.80M | $31.40M | $28.14M | +42.3% |
| Other Operational Infrastructure and Advisory Support [Member] | $21.68M | $36.37M | $40.43M | $18.87M | $15.96M | $29.31M | $26.89M | +35.8% |
| Research and Development Software, Facilities and Other Strategic Support [Member] | $10.10M | $11.73M | $20.09M | $4.14M | $3.27M | $12.02M | $10.81M | +208.7% |
| Depreciation Expense [Member] | $1.15M | $1.24M | $2.56M | $1.25M | $1.23M | $2.49M | $2.45M | -6.2% |
By product or service
By region
From the segment and revenue-disaggregation notes of Cogent Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.